Latest Iga News

Metcash has exercised its first right to acquire Queensland’s Peries Group in a debt-funded deal valued at an estimated $80 million to $85 million. The transaction would add 15 IGA supermarkets and around $264 million in annual retail sales, subject to ACCC approval and other conditions.

Metcash Limited posted a steady FY26 performance, with group revenue rising to $19.6 billion and EBITDA up 1.9%, driven by growth in Food and digital channels despite challenges in Hardware.

Dimerix Limited (ASX: DXB) has inked its fifth regional licensing agreement with Everest Medicines, boosting potential milestone payments to A$1.9 billion and expanded its kidney disease pipeline through the acquisition of DMX-652. The Phase 3 ACTION3 trial for DMX-200 remains statistically robust, with funding secured to advance both clinical programs.

Metcash Limited posted a modest rise in FY26 revenue and EBITDA, driven by strong Food segment growth and strategic acquisitions, while facing pressure in Hardware margins and suspending its Dividend Reinvestment Plan.

Metcash Limited reported steady FY26 half-year results with modest revenue growth, strong cash flow, and resilience amid tobacco sales decline. The company’s digital B2B marketplace 'Sorted' is rapidly expanding, underpinning future growth prospects.

Metcash Limited reported a marginal rise in sales revenue to $8.48 billion for 1H26, with underlying EBITDA up 2% driven by Food pillar growth, while EBIT declined 2.4% amid challenges in Liquor and Hardware segments. The Board declared an interim fully franked dividend of 8.5 cents per share.

Metcash Limited reported solid FY25 results with revenue rising 8.9% to $17.3 billion, driven by strong Food growth and Hardware’s late recovery. Despite a slight dip in underlying profit after tax, the company’s strategic mergers and acquisitions position it well for future expansion.

Immuron has submitted its Phase 2 clinical study report for Travelan® to the FDA, revealing statistically significant immunological and microbiome benefits. The company is preparing to engage the FDA for Phase 3 trial discussions while progressing a large field study with military personnel.